These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21642688)

  • 21. Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.
    Naci H; Wouters OJ; Gupta R; Ioannidis JPA
    Milbank Q; 2017 Jun; 95(2):261-290. PubMed ID: 28589600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of the FDA in the national cancer program: friend or foe?
    Schein PS; Scheffler B; Carter S
    Oncologist; 2003; 8(6):501-6. PubMed ID: 14657526
    [No Abstract]   [Full Text] [Related]  

  • 23. Building comparative efficacy and tolerability into the FDA approval process.
    O'Connor AB
    JAMA; 2010 Mar; 303(10):979-80. PubMed ID: 20215612
    [No Abstract]   [Full Text] [Related]  

  • 24. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 25. Managed care outlook. Oncologists: FDA needs to speed up approval of cancer-fighting drugs.
    Manag Care; 2002 Jun; 11(6):56. PubMed ID: 12098877
    [No Abstract]   [Full Text] [Related]  

  • 26. Oncology drugs enter the US market faster than in Europe but cost more.
    Mitka M
    JAMA; 2012 Aug; 308(6):555. PubMed ID: 22871850
    [No Abstract]   [Full Text] [Related]  

  • 27. Vouching for access.
    Nat Med; 2016 Jul; 22(7):693. PubMed ID: 27387878
    [No Abstract]   [Full Text] [Related]  

  • 28. The role of the FDA in drug development: implications for improved access to new HIV/AIDS therapies. Testimony before the Subcommittee on Health and Environment-Committee on Commerce concerning FDA reform bill HR 3199.
    Cooper EC; Sanders S
    AIDS Patient Care STDS; 1996 Aug; 10(4):213-20. PubMed ID: 11361591
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmaceuticals ... should the U.S. Food and Drug Administration be remodeled.
    Hosp Health Netw; 1996 Jan; 70(1):17. PubMed ID: 8541919
    [No Abstract]   [Full Text] [Related]  

  • 30. Remarks of the Lead Deputy Commissioner of the Food and Drug Administration.
    Friedman MA
    Food Drug Law J; 1998; 53(1):19-23. PubMed ID: 11795333
    [No Abstract]   [Full Text] [Related]  

  • 31. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
    Tsimberidou AM; Braiteh F; Stewart DJ; Kurzrock R
    J Clin Oncol; 2009 Dec; 27(36):6243-50. PubMed ID: 19826112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accelerated approval of oncology products: a decade of experience.
    Dagher R; Johnson J; Williams G; Keegan P; Pazdur R
    J Natl Cancer Inst; 2004 Oct; 96(20):1500-9. PubMed ID: 15494600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Better prioritization may speed approval of adjuvant therapies in breast cancer.
    Tuma RS
    J Natl Cancer Inst; 2008 Jun; 100(12):842-4. PubMed ID: 18544735
    [No Abstract]   [Full Text] [Related]  

  • 34. Oncology's first Phase 0 trial.
    Rowan K
    J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
    [No Abstract]   [Full Text] [Related]  

  • 35. Working together to enhance the efficiency of medical product development.
    Sanhai WR
    J Nucl Med; 2008 Jun; 49(6):43N-45N. PubMed ID: 18511823
    [No Abstract]   [Full Text] [Related]  

  • 36. FDA advisory panel voices persistent safety concerns.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Apr; 98(7):439. PubMed ID: 16595778
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA approves sorafenib for patients with inoperable liver cancer.
    Lang L
    Gastroenterology; 2008 Feb; 134(2):379. PubMed ID: 18242200
    [No Abstract]   [Full Text] [Related]  

  • 38. Case Study for Lean Management in the Public Sector: Improving Combination Product Review at the Food & Drug Administration.
    Rappel MJ; Hunter NL; Alexandrow AI; Hair KO; Sherman RE; Califf RM
    Clin Transl Sci; 2017 May; 10(3):124-127. PubMed ID: 28079301
    [No Abstract]   [Full Text] [Related]  

  • 39. Social norms and the evolution of drug regulation in the U.S.: implications for access to medications for HIV disease.
    Smith SR; Kirking DM
    AIDS Public Policy J; 1999; 14(3):105-16. PubMed ID: 10935047
    [No Abstract]   [Full Text] [Related]  

  • 40. Accelerated approval scrutinized: confirmatory phase 4 studies on new drugs languish.
    Mitka M
    JAMA; 2003 Jun; 289(24):3227-9. PubMed ID: 12824196
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.